Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC36, a once-monthly, potentially best-in-class subcutaneously administered amylin receptor agonist, as a clinical ...
Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and ...
Background Research has shown that workers in non-standard (eg, temporary and part-time) employment experience poorer health ...
OpenAI has published 56 top ChatGPT prompts used by Indian students from top colleges to help study smarter and plan campus ...
Using semaglutide or tirzepatide for less than 2 years can cost as much as a Roux-en-Y gastric bypass — a one-time procedure ...
Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and ...
In the third quarter, the partnership returned +1.4%, net of all fees and expenses, bringing the year-to-date net return to ...
Seven years in, the Seattle Promise Program, which offers free tuition to Seattle Colleges for SPS graduates, has increased ...
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights. Q3 ...
Relay Therapeutics, Inc. leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety & efficacy. Learn more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback